Insmed (NASDAQ:INSM) Downgraded to “Sell” at StockNews.com

StockNews.com cut shares of Insmed (NASDAQ:INSM) from a hold rating to a sell rating in a research note published on Monday.

Several other equities research analysts have also weighed in on INSM. Barclays upped their price objective on Insmed from $37.00 to $40.00 and gave the company an overweight rating in a research note on Thursday, April 11th. Wolfe Research started coverage on Insmed in a research note on Thursday, February 15th. They set an outperform rating and a $42.00 price objective for the company. UBS Group began coverage on shares of Insmed in a research note on Tuesday, February 27th. They issued a buy rating and a $46.00 target price on the stock. Wells Fargo & Company reiterated an overweight rating and set a $55.00 target price on shares of Insmed in a research report on Monday, April 1st. Finally, Guggenheim boosted their price target on shares of Insmed from $52.00 to $54.00 and gave the company a buy rating in a research report on Tuesday, February 27th. One investment analyst has rated the stock with a sell rating and twelve have given a buy rating to the company’s stock. According to data from MarketBeat.com, the stock currently has an average rating of Moderate Buy and a consensus target price of $44.92.

Insmed Price Performance

Shares of INSM stock opened at $26.00 on Monday. The stock has a market cap of $3.86 billion, a P/E ratio of -4.87 and a beta of 0.93. The stock has a fifty day moving average price of $26.61 and a 200 day moving average price of $27.07. Insmed has a one year low of $18.08 and a one year high of $32.00.

Insmed (NASDAQ:INSM) last issued its earnings results on Thursday, February 22nd. The biopharmaceutical company reported ($1.28) earnings per share for the quarter, missing the consensus estimate of ($1.13) by ($0.15). The firm had revenue of $83.70 million for the quarter, compared to analyst estimates of $82.15 million. The business’s quarterly revenue was up 41.1% compared to the same quarter last year. During the same quarter in the prior year, the business posted ($1.20) EPS. Equities research analysts anticipate that Insmed will post -4.65 EPS for the current year.

Hedge Funds Weigh In On Insmed

Several hedge funds have recently added to or reduced their stakes in the company. International Assets Investment Management LLC acquired a new stake in shares of Insmed during the 4th quarter worth approximately $25,000. Fidelis Capital Partners LLC bought a new stake in shares of Insmed during the 1st quarter valued at $34,000. Headlands Technologies LLC bought a new stake in shares of Insmed during the 1st quarter valued at $59,000. China Universal Asset Management Co. Ltd. boosted its position in shares of Insmed by 106.8% in the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 3,698 shares of the biopharmaceutical company’s stock worth $93,000 after purchasing an additional 1,910 shares during the last quarter. Finally, Quarry LP acquired a new stake in shares of Insmed during the fourth quarter worth $116,000.

About Insmed

Insmed Incorporated is a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases. Insmed’s first commercial product is ARIKAYCE® (amikacin liposome inhalation suspension), which is approved in the United States for the treatment of Mycobacterium avium complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options.